Vinod K. Audimoolam, Mathew R. Foxton, Kosh Agarwal, John G. O'Grady, Michael A. Heneghan – 15 January 2010

Kate R. Muller, Robert Padbury, Gary P. Jeffrey, Nicola K. Poplawski, Philip Thompson, Anne Tonkin, Hugh A. J. Harley – 15 January 2010 – Transthyretin amyloid polyneuropathy, caused by mutations in the transthyretin gene, is a progressive condition for which liver transplantation is an established treatment. Favorable outcomes have been described in patients with the most common transthyretin mutation, Val30Met, but outcomes have been variable in patients with other mutations.

Toshimi Kaido, Yasutsugu Takada, Shinji Uemoto – 15 January 2010

Sophie Dupuis‐Girod, Anne‐Laure Chesnais, Isabelle Ginon, Jérôme Dumortier, Jean‐Christophe Saurin, Gérard Finet, Evelyne Decullier, Denis Marion, Henri Plauchu, Olivier Boillot – 12 January 2010 – Hepatic involvement occurs in up to 74% of patients with hereditary hemorrhagic telangiectasia (HHT) and is characterized by a spectrum of arteriovenous malformations. Three different types of intrahepatic shunting may be present: hepatic artery to hepatic veins, hepatic artery to portal vein, and portal vein to hepatic vein.

Frédéric Bert, Beatrice Larroque, Catherine Paugam‐Burtz, Sylvie Janny, Francois Durand, Fédérica Dondero, Dominique‐Charles Valla, Jacques Belghiti, Richard Moreau, Marie‐Hélène Nicolas‐Chanoine – 12 January 2010 – Bloodstream infections (BSIs) are a major cause of mortality in liver transplant recipients. The incidence, microbiology, and outcome of BSIs in the first year after liver transplantation were analyzed in 704 patients who underwent transplantation at a single center between 1997 and 2007. BSIs occurred in 205 (29.1%) of the 704 patients.

Ana‐Paula Barreiros, Felix Post, Maria Hoppe‐Lotichius, Reinhold P. Linke, Christian F. Vahl, Hans‐Joachim Schäfers, Peter R. Galle, Gerd Otto – 12 January 2010 – Liver transplantation (LT) is the only curative option for patients with familial amyloid polyneuropathy (FAP) at present. Twenty patients with FAP underwent LT between May 1998 and June 2007. Transthyretin mutations included predominantly the Val30Met mutation but also 10 other mutations.

See Ching Chan, Chung Mau Lo, Sheung Tat Fan – 12 January 2010

Yukihiro Sanada, Youichi Kawano, Koichi Mizuta, Satoshi Egami, Makoto Hayashida, Taiichi Wakiya, Takehito Fujiwara, Yasunaru Sakuma, Masanobu Hydo, Manabu Nakata, Yoshikazu Yasuda, Hideo Kawarasaki – 12 January 2010 – Portal vein complications after liver transplantation (LT) are serious complications that can lead to graft liver failure. Although the treatment of interventional radiology (IVR) by means of balloon dilatation for portal vein stenosis (PVS) after LT is an effective method, the high rate of recurrent PVS is an agonizing problem.

Omar Barakat, R. Patrick Wood, Claire F. Ozaki, Victor Ankoma‐Sey, Joseph Galati, Mark Skolkin, Barry Toombs, Mary Round, Warren Moore, Luis Mieles – 12 January 2010 – In selected patients, locoregional therapy (LRT) has been successful in downstaging advanced hepatocellular carcinoma (HCC) so that the conventional criteria for liver transplantation (LT) can be met. However, the factors that predict successful treatment are largely unidentified. To determine these factors, we analyzed our experience with multimodal LRT in downstaging advanced HCC before LT in a retrospective cohort study.

Maria Teresa Melgosa, Giovanni L. Ricci, Juan Carlos García‐Pagan, Isabel Blanco, Pilar Escribano, Juan G. Abraldes, Josep Roca, Jaume Bosch, Joan Albert Barberà – 12 January 2010 – Portopulmonary hypertension (PoPH) is a serious condition without an established treatment. Drugs used to treat pulmonary hypertension may have detrimental effects on portal hypertension. This study was designed to assess in patients with PoPH the acute effects of inhaled iloprost (iILO) on pulmonary and hepatic hemodynamics and to evaluate the clinical outcome after 12 months of treatment.